Concepedia

Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany

Aditya Sardesai, Peter Quon, Sandra Milev, Joseph C. Cappelleri, Agnes Kisser, Irene Modesto, Puza P. Sharma

Journal of Medical Economics · 2021 · 14 citations · 25 references

Open access

Abstract

The results of this economic model suggest tofacitinib is a cost-effective treatment option for patients with moderate to severe UC in Germany.

References

25

null · Philosophy study · 2016 · 28.3K citations · Full text

Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis

Paul Rutgeerts, William J. Sandborn, Brian G. Feagan et al. · New England Journal of Medicine · 2005 · 3.8K citations · Full text

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

Brian G. Feagan, Paul Rutgeerts, Bruce E. Sands et al. · New England Journal of Medicine · 2013 · 2.8K citations · Full text

Epidemiology and Natural History of Inflammatory Bowel Diseases

Jacques Cosnes, Corinne Gower‐Rousseau, Philippe Seksik et al. · Gastroenterology · 2011 · 2.1K citations · Full text

Inflammation, Clinical Epidemiology, Natural History +5

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

William J. Sandborn, Chinyu Su, Bruce E. Sands et al. · New England Journal of Medicine · 2017 · 1.7K citations · Full text